Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158979 | 1.00 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3MEN1LMNA | |
| SCHEMBL82935 | 1.00 | — | — | |
| SCHEMBL27992068 | 1.00 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3MEN1LMNA | |
| SCHEMBL27560935 | 1.00 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3MEN1LMNA | |
| SCHEMBL18854121 | 1.00 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3MEN1LMNA | |
| SCHEMBL348693 | 0.97 | — | — | |
| SCHEMBL4955062 | 0.97 | — | — | |
| SCHEMBL3679748 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL21056379 | 0.95 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL21056375 | 0.95 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101198604-A | NPY antagonists, their preparation and use | CEREP (FR) | 2008-06-11 | — | — | CN | claimed |
| CN-1950357-A | Imidazole derivatives used as TAFIA inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-04-18 | — | — | CN | claimed |
| CN-1926148-A | Beta-aminoacid-derivatives as factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-03-07 | — | — | CN | claimed |
| CN-1926137-A | Pyrrole-derivatives as factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-03-07 | — | — | CN | claimed |
| CN-1791598-A | benzimidazole derivatives as factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-06-21 | — | — | CN | claimed |
| CN-1791601-A | azaindole derivatives as factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-06-21 | — | — | CN | claimed |
| EP-0476515-A1 | New amino acid derivatives, a process for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-25 | — | — | EP | claimed |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10654874-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-19 | — | — | US | disclosed |
| EP-2603513-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF AS AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-29 | — | — | US | disclosed |
| CN-110099869-A | Thermally responsive solution and method of use thereof | 阿克福特斯技术有限公司 | 2019-08-06 | — | — | CN | disclosed |
| CN-1152858-C | Method for co-producing cyclic lactam and cyclic amine | BASF | 2004-06-09 | — | — | CN | disclosed |
| CN-1430610-A | Substituted 1-aminoalkyllactam compounds and their use as muscarinic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2003-07-16 | — | — | CN | disclosed |
| US-6420613-B1 | CHEMICAL REDUCTION WITH TRICHLOROSILANE | TOKUYAMA CORPORATION (JP) | 2002-07-16 | — | — | US | disclosed |
| CN-1318050-A | Method for co-producing cyclic lactam and cyclic amine | BASF AG (DE) | 2001-10-17 | — | — | CN | disclosed |
| CN-1316996-A | Method for joint production of cyclic lactam and cyclic amine | BASF AG (DE) | 2001-10-10 | — | — | CN | disclosed |
| EP-1086941-A1 | PROCESS FOR PREPARING REDUCTANTS OF UNSATURATED ORGANIC COMPOUNDS BY THE USE OF TRICHLOROSILANE AND REDUCING AGENTS | TOKUYAMA CORPORATION (JP) | 2001-03-28 | — | — | EP | disclosed |
| EP-0476515-A1 | New amino acid derivatives, a process for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | SLC6A2 77/4885SLC6A4 84/4885SLC6A3 64/4885 |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | SLC6A2 77/4885SLC6A4 84/4885SLC6A3 64/4885 |
| US-10654874-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | SLC6A2 77/4885SLC6A4 84/4885SLC6A3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.